Analytical Data
-
Gene name
HRH1
- Application
-
Alternative Names
Short name:H1R Short name:HH1R
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P35367
-
Expression Region
211-416aa
-
Molecular Weight
27.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HRH1, or the histamine receptor H1, is a G-protein coupled receptor that plays a crucial role in mediating various physiological responses to histamine, including allergic reactions and neurogenic inflammation. The study of HRH1 recombinant proteins is gaining significance due to their potential applications in drug development, particularly for allergic disorders, asthma, and other histamine-related conditions. Understanding HRH1 structure and function through recombinant protein studies allows researchers to investigate its signaling pathways, ligand-binding characteristics, and interaction with downstream effectors, which is vital for designing specific antagonists or agonists. Furthermore, the advancements in recombinant DNA technology facilitate the production of HRH1 proteins in various expression systems, enabling detailed biochemical analyses and the development of therapeutic agents. Investigating HRH1 at the molecular level not only enhances our comprehension of histaminergic signaling but also contributes significantly to the identification of novel treatment strategies for managing a wide range of diseases associated with histamine dysregulation. Thus, HRH1 recombinant protein research represents a promising frontier in pharmacology and therapeutic innovation.
